This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wei, D. Articles by Xie, K. Search for Related Content PubMed PubMed Citation Articles by Wei, D. Articles by Xie, K.

Celecoxib Inhibits Vascular Endothelial Growth Factor Expression in and Reduces Angiogenesis and Metastasis of Human Pancreatic Cancer via Suppression of Sp1 Transcription Factor Activity

¹ Departments of Gastrointestinal Medical Oncology and ² Cancer Biology, The University of Texas M. D. Anderson Cancer Center, and ³ Program in Cancer Biology, The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, Texas

The aggressive biology of human pancreatic adenocarcinoma has been linked with overexpression of vascular endothelial growth factor (VEGF). Constitutive activation of the transcription factor Sp1 plays a critical role in VEGF overexpression. Recent studies indicated that celecoxib, a selective cyclooxygenase-2 inhibitor, exhibits potent antitumor activity. However, the underlying molecular mechanisms of this activity remain unclear. In the present study, we used a pancreatic cancer model to determine the role of Sp1 in the antitumor activity of celecoxib. Treatment of various pancreatic cancer cells with celecoxib suppressed VEGF expression at both the mRNA and protein level in a dose-dependent manner. VEGF promoter deletion and point mutation analyses indicated that a region between nucleotide -109 and -61 and its intact Sp1-binding sites were required for the inhibition of VEGF promoter activity by celecoxib. Also, celecoxib treatment reduced both Sp1 DNA binding activity and transactivating activity. This decreased activity correlated with reduced Sp1 protein and its phosphorylation as determined using Western blot analysis. Furthermore, in an orthotopic pancreatic cancer animal model, celecoxib treatment inhibited tumor growth and metastasis. The antitumor activity was consistent with inhibition of angiogenesis as determined by evaluating tumor microvessel formation, which correlated with decreased Sp1 activity and VEGF expression. Collectively, our data provide a novel molecular mechanism for the antitumor activity of celecoxib and may help further improve its effectiveness in controlling pancreatic cancer growth and metastasis.

This article has been cited by other articles:

				M. Benish, I. Bartal, Y. Goldfarb, B. Levi, R. Avraham, A. Raz, and S. Ben-Eliyahu Perioperative Use of {beta}-blockers and COX-2 Inhibitors May Improve Immune Competence and Reduce the Risk of Tumor Metastasis Ann. Surg. Oncol., July 1, 2008; 15(7): 2042 - 2052. [Abstract] [Full Text] [PDF]

				D. Wei, M. Kanai, Z. Jia, X. Le, and K. Xie Kruppel-like Factor 4 Induces p27Kip1 Expression in and Suppresses the Growth and Metastasis of Human Pancreatic Cancer Cells Cancer Res., June 15, 2008; 68(12): 4631 - 4639. [Abstract] [Full Text] [PDF]

				C.-C. Wu, J.-C. Lin, S.-C. Yang, C.-W. Lin, J. J.W. Chen, J.-Y. Shih, T.-M. Hong, and P.-C. Yang Modulation of the expression of the invasion-suppressor CRMP-1 by cyclooxygenase-2 inhibition via reciprocal regulation of Sp1 and C/EBP{alpha} Mol. Cancer Ther., June 1, 2008; 7(6): 1365 - 1375. [Abstract] [Full Text] [PDF]

				R.-N. Chen, Y.-H. Huang, C.-T. Yeh, C.-H. Liao, and K.-H. Lin Thyroid Hormone Receptors Suppress Pituitary Tumor Transforming Gene 1 Activity in Hepatoma Cancer Res., March 15, 2008; 68(6): 1697 - 1706. [Abstract] [Full Text] [PDF]

				S. Kesari, D. Schiff, L. Doherty, D. C. Gigas, T. T. Batchelor, A. Muzikansky, A. O'Neill, J. Drappatz, A. S. Chen-Plotkin, N. Ramakrishna, et al. Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults Neuro-oncol, July 1, 2007; 9(3): 354 - 363. [Abstract] [Full Text] [PDF]

				Z. Jia, J. Zhang, D. Wei, L. Wang, P. Yuan, X. Le, Q. Li, J. Yao, and K. Xie Molecular Basis of the Synergistic Antiangiogenic Activity of Bevacizumab and Mithramycin A Cancer Res., May 15, 2007; 67(10): 4878 - 4885. [Abstract] [Full Text] [PDF]

				M. Abdelrahim, C. H. Baker, J. L. Abbruzzese, D. Sheikh-Hamad, S. Liu, S. D. Cho, K. Yoon, and S. Safe Regulation of Vascular Endothelial Growth Factor Receptor-1 Expression by Specificity Proteins 1, 3, and 4 in Pancreatic Cancer Cells Cancer Res., April 1, 2007; 67(7): 3286 - 3294. [Abstract] [Full Text] [PDF]

				Y. E. KWAK, N. K. JEON, J. KIM, and E. J. LEE The Cyclooxygenase-2 Selective Inhibitor Celecoxib Suppresses Proliferation and Invasiveness in the Human Oral Squamous Carcinoma Ann. N.Y. Acad. Sci., January 1, 2007; 1095(1): 99 - 112. [Abstract] [Full Text] [PDF]

				R. Soo, J Wu, A Aggarwal, Q Tao, W Hsieh, T Putti, K. Tan, W. Soon, Y. Lai, B Mow, et al. Celecoxib reduces microvessel density in patients treated with nasopharyngeal carcinoma and induces changes in gene expression Ann. Onc., November 1, 2006; 17(11): 1625 - 1630. [Abstract] [Full Text] [PDF]

				M. Kanai, D. Wei, Q. Li, Z. Jia, J. Ajani, X. Le, J. Yao, and K. Xie Loss of kruppel-like factor 4 expression contributes to sp1 overexpression and human gastric cancer development and progression. Clin. Cancer Res., November 1, 2006; 12(21): 6395 - 6402. [Abstract] [Full Text] [PDF]

				X. de Leval, T. Dassesse, J.-M. Dogne, D. Waltregny, A. Bellahcene, V. Benoit, B. Pirotte, and V. Castronovo Evaluation of Original Dual Thromboxane A2 Modulators as Antiangiogenic Agents J. Pharmacol. Exp. Ther., September 1, 2006; 318(3): 1057 - 1067. [Abstract] [Full Text] [PDF]

				M. Abdelrahim, C. H. Baker, J. L. Abbruzzese, and S. Safe Tolfenamic acid and pancreatic cancer growth, angiogenesis, and Sp protein degradation. J Natl Cancer Inst, June 21, 2006; 98(12): 855 - 868. [Abstract] [Full Text] [PDF]

				S. Grosch, T. J. Maier, S. Schiffmann, and G. Geisslinger Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. J Natl Cancer Inst, June 7, 2006; 98(11): 736 - 747. [Abstract] [Full Text] [PDF]

				E. Giovannetti, V. Mey, S. Nannizzi, G. Pasqualetti, M. Del Tacca, and R. Danesi Pharmacogenetics of anticancer drug sensitivity in pancreatic cancer. Mol. Cancer Ther., June 1, 2006; 5(6): 1387 - 1395. [Abstract] [Full Text] [PDF]

				Y. Moon, F. G. Bottone Jr., M. F. McEntee, and T. E. Eling Suppression of tumor cell invasion by cyclooxygenase inhibitors is mediated by thrombospondin-1 via the early growth response gene Egr-1 Mol. Cancer Ther., October 1, 2005; 4(10): 1551 - 1558. [Abstract] [Full Text] [PDF]

				X. Zhang, Z. Chen, M. S. Choe, Y. Lin, S.-Y. Sun, H. S. Wieand, H. J. C. Shin, A. Chen, F. R. Khuri, and D. M. Shin Tumor Growth Inhibition by Simultaneously Blocking Epidermal Growth Factor Receptor and Cyclooxygenase-2 in a Xenograft Model Clin. Cancer Res., September 1, 2005; 11(17): 6261 - 6269. [Abstract] [Full Text] [PDF]

				C T Tong, S A Howard, H R Shah, K R Van Quill, E T Lin, H E Grossniklaus, and J M O'Brien Effects of celecoxib in human retinoblastoma cell lines and in a transgenic murine model of retinoblastoma Br. J. Ophthalmol., September 1, 2005; 89(9): 1217 - 1220. [Abstract] [Full Text] [PDF]

				M. Abdelrahim and S. Safe Cyclooxygenase-2 Inhibitors Decrease Vascular Endothelial Growth Factor Expression in Colon Cancer Cells by Enhanced Degradation of Sp1 and Sp4 Proteins Mol. Pharmacol., August 1, 2005; 68(2): 317 - 329. [Abstract] [Full Text] [PDF]

				D. Wei, W. Gong, S. C. Oh, Q. Li, W. D. Kim, L. Wang, X. Le, J. Yao, T. T. Wu, S. Huang, et al. Loss of RUNX3 Expression Significantly Affects the Clinical Outcome of Gastric Cancer Patients and Its Restoration Causes Drastic Suppression of Tumor Growth and Metastasis Cancer Res., June 1, 2005; 65(11): 4809 - 4816. [Abstract] [Full Text] [PDF]

				F. G. Bottone Jr., Y. Moon, J. S. Kim, B. Alston-Mills, M. Ishibashi, and T. E. Eling The anti-invasive activity of cyclooxygenase inhibitors is regulated by the transcription factor ATF3 (activating transcription factor 3) Mol. Cancer Ther., May 1, 2005; 4(5): 693 - 703. [Abstract] [Full Text] [PDF]

				D. Wei, W. Gong, M. Kanai, C. Schlunk, L. Wang, J. C. Yao, T.-T. Wu, S. Huang, and K. Xie Drastic Down-regulation of Kruppel-Like Factor 4 Expression Is Critical in Human Gastric Cancer Development and Progression Cancer Res., April 1, 2005; 65(7): 2746 - 2754. [Abstract] [Full Text] [PDF]

				G. Pages and J. Pouyssegur Transcriptional regulation of the Vascular Endothelial Growth Factor gene-a concert of activating factors Cardiovasc Res, February 15, 2005; 65(3): 564 - 573. [Abstract] [Full Text] [PDF]